Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by ORIC Pharmaceuticals
< Previous
1
2
3
Next >
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 23, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 09, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
August 12, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
August 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
July 16, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
May 29, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today